Search

Viking Therapeutics Inc

Fermé

SecteurSoins de santé

29.92 -4.65

Résumé

Variation du prix de l'action

24h

Actuel

Min

29.67

Max

31.52

Chiffres clés

By Trading Economics

Revenu

30M

-128M

BPA

-1.1

Employés

65

EBITDA

30M

-128M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+185.71% upside

Dividendes

By Acuity

Prochains Résultats

21 oct. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-371M

3.7B

Ouverture précédente

34.57

Clôture précédente

29.92

Sentiment de l'Actualité

By Acuity

50%

50%

129 / 339 Classement par Healthcare

Viking Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

15 sept. 2026, 23:02 UTC

Viking Therapeutics Inc shares are higher during after-market hours, reflecting broader market trends despite recent economic indicators suggesting a slowdown in manufacturing.

14 sept. 2026, 19:36 UTC

Viking Therapeutics Inc shares are lower, continuing a trend of declines amid broader market weakness and rising crude oil prices affecting sentiment.

11 sept. 2026, 23:06 UTC

Viking Therapeutics Inc. shares are higher in after-market trading, despite routine fluctuations, and remain below their 20-day moving average.

10 sept. 2026, 20:07 UTC

Correlated Moves
Social Media

Viking Therapeutics Inc shares are lower, influenced by a declining broader market and volatility in the biotech sector amid rising Treasury yields and inflation concerns.

9 sept. 2026, 23:11 UTC

Viking Therapeutics Inc shares are higher in after-market trading, recovering from earlier lows despite being below the 20-day moving average. No specific news was identified.

2 sept. 2026, 19:46 UTC

Viking Therapeutics Inc shares are lower today, pulling back from earlier session highs amid broader market concerns over rising U.S. Treasury yields.

31 août 2026, 19:36 UTC

Viking Therapeutics shares are higher today, despite earlier pressure, amid broader market dynamics influenced by rising interest rate expectations following comments from the Fed.

29 août 2026, 00:01 UTC

Viking Therapeutics Inc shares rose in after-market trading, reflecting a notable increase since Friday's close, despite no specific news driving the movement.

28 août 2026, 23:36 UTC

Viking Therapeutics Inc. shares are higher in after-market trading, gaining since Friday's close, despite fluctuations and remaining below the 20-day moving average.

27 août 2026, 23:02 UTC

Viking Therapeutics Inc shares are higher in after-market hours following notable volatility during the session, despite no specific news to explain the movement.

26 août 2026, 19:16 UTC

Viking Therapeutics Inc shares are higher today, though no specific news was identified to explain the price movement. The stock remains above its 20-day moving average.

25 août 2026, 23:16 UTC

Viking Therapeutics shares are lower in after-market hours amid broader market volatility, with falling oil prices and geopolitical developments affecting investor sentiment.

24 août 2026, 19:56 UTC

Social Media

Viking Therapeutics Inc shares are lower today, continuing a decline since Friday. Social media discussions highlight anticipation for upcoming data before Labor Day.

20 août 2026, 20:06 UTC

Macro Event
Social Media

Viking Therapeutics Inc shares are lower, impacted by labor market data and heightened volatility, despite social media discussions suggesting potential recovery from a clinical trial.

19 août 2026, 23:16 UTC

Viking Therapeutics Inc shares are higher in after-market hours, reflecting a gain since Wednesday's close and remaining above the 20-day moving average.

18 août 2026, 19:16 UTC

Viking Therapeutics Inc shares are lower today, with no specific news driving the decline amid rising U.S. Treasury yields affecting the biotechnology sector.

17 août 2026, 23:06 UTC

Viking Therapeutics Inc shares are higher in after-market trading, reflecting unusual strength. No specific company news was identified to explain the price movement.

14 août 2026, 23:06 UTC

Viking Therapeutics Inc shares are lower in after-market hours, trading at the lower end of their one-month range and below the 20-day moving average.

13 août 2026, 23:16 UTC

Viking Therapeutics Inc shares are lower in after-market trading, with no specific news identified to explain the decline. The stock is near its one-month low.

12 août 2026, 23:26 UTC

Viking Therapeutics Inc is trading lower in after-market hours, reflecting notable weakness with no specific news identified to explain the decline.

7 août 2026, 19:36 UTC

Social Media

Viking Therapeutics is rising amid broader market gains and anticipation of VK2809 trial results, with analysts noting potential for improved market position.

6 août 2026, 23:16 UTC

Social Media

Viking Therapeutics Inc gains in after-market hours amid discussions on pharmacokinetic modeling and anticipated VKTX maintenance readout results.

5 août 2026, 22:51 UTC

Viking Therapeutics Inc. shares are lower in after-market hours, continuing a decline from Wednesday's close amid unusual volatility and trading below the 20-day moving average.

4 août 2026, 23:02 UTC

Social Media

Viking Therapeutics Inc shares are lower in after-market hours amid routine trading. The stock remains below its 20-day moving average.

3 août 2026, 23:06 UTC

Viking Therapeutics shares are higher in after-market trading, reflecting positive sentiment from stronger-than-expected manufacturing PMI data indicating sector growth.

31 juil. 2026, 23:51 UTC

Viking Therapeutics Inc is higher in after-market trading, recovering from earlier session lows after four consecutive declines. The stock remains below its 20-day moving average.

30 juil. 2026, 23:56 UTC

News

Viking Therapeutics Inc. shows a modest gain in after-market hours amid a wave of biopharmaceutical mergers, including Vertex's $10 billion acquisition of Crinetics.

29 juil. 2026, 23:21 UTC

Social Media
News

Viking Therapeutics reported a Q2 loss of $1.10 per share, better than expected. The company highlighted progress in its obesity treatment pipeline.

28 juil. 2026, 23:11 UTC

News

Viking Therapeutics shares are lower in after-market hours amid ongoing challenges and a significant decline over the past two years. Analysts maintain a bullish outlook.

27 juil. 2026, 23:56 UTC

Viking Therapeutics Inc shares are lower in after-market hours, reflecting a lack of specific news and remaining below the 20-day moving average.

Comparaison

Variation de prix

Viking Therapeutics Inc prévision

Objectif de Prix

By TipRanks

185.71% hausse

Prévisions sur 12 Mois

Moyen 90.083 USD  185.71%

Haut 114 USD

Bas 65 USD

Basé sur 14 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

14 ratings

14

Achat

0

Maintien

0

Vente

Sentiment

By Acuity

129 / 339Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Viking Therapeutics Inc

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
help-icon Live chat